Navigation Links
Nektar Consolidates Research at Its State-of-the-Art R&D Center Located in San Francisco at Mission Bay
Date:3/20/2012

in no change to the company's most recent financial guidance provided on the February 29, 2012 webcast conference call to review the company's 2011 financial results.  An audio replay of that conference call will remain available the company's website www.nektar.com in the Investor Relations Section under Financial Calendar & Presentations.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms.  Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which is being evaluated in Phase 3 clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation.  This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid.  NKTR-181, a novel mu-opioid analgesic in development to treat chronic pain, has completed Phase 1 development and is being prepared for Phase 2 development.  In oncology, NKTR-102 is being evaluated in a Phase 3 clinical study for the treatment of metastatic breast cancer and in Phase 2 studies for the treatment of ovarian and colorectal cancers.

Nektar's technology has enabled seven approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.  Additional development-stage products that leverage Nektar's proprietary technology platform include peginesatide, for which Affymax and partner Takeda submitted a new drug application to the United
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
10. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
11. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 Research and Markets  has ... Market 2014-2018" report to their offering. ... needle is a hollow needle commonly used with a ... to extract fluids from it. A hypodermic needle is ... substances that cannot be ingested. Hypodermic needles are broadly ...
(Date:7/11/2014)... , July 11, 2014 ... Market Research "Endoscopy Devices Market (Endoscopes, Endoscopic Operative Devices, ... Growth, Trends and Forecast, 2013-2019" the global endoscopy devices ... and is expected to grow at a CAGR of ... value of USD 36.9 billion in 2019. ...
(Date:7/11/2014)... , July 11, 2014 Neurelis, Inc. ("Neurelis") ... to end the option held by Biotie to purchase ... development of NRL-1 (intranasal diazepam) for pediatric and adult ... Over the past year, Biotie has advanced the development ... for the pivotal clinical work required for NDA submission ...
Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... Concord Medical Services Holdings Limited ("Concord Medical" or ... operator of the largest network of radiotherapy and ... it has signed an Memorandum of Understating ("MOU") ... Electric International Operations Company, Inc. and GE Medical ...
... 2011 China Nuvo Solar Energy, Inc. (OTCQB: CNUV) ... with Tandem Receivable Solutions to a western distributorship. Tandem, ... committed to assisting the Company from sales through collections ... Tom Toland, CEO of SurgLine stated, "As business ...
Cached Medicine Technology:Concord Medical and GE Healthcare Sign MOU for Preferred Partnership in China 2China Nuvo Solar Target Acquisition SurgLine Announces Agreement With Western U.S. Distributor 2China Nuvo Solar Target Acquisition SurgLine Announces Agreement With Western U.S. Distributor 3
(Date:7/13/2014)... Wa (PRWEB) July 13, 2014 According ... by Vkool.com, this is a comprehensive guide that features ... deal with KP (keratosis pilaris). This guide ... 1: What Is Keratosis Pilaris? ,     Chapter 2: ... I Know If I Have KP? ,     Chapter ...
(Date:7/12/2014)... Fadhits.com, a well-known wedding dress manufacturer and retailer, has added ... to its product line. In addition, the company has launched ... bring more benefits for its loyal fans. All its ... to 72% off. , As a leader in the garment ... is a good place for ladies who want to purchase ...
(Date:7/12/2014)... 12, 2014 The Passenger Information System ... 2013 to $20,341.36 million by 2019, at an expected ... 2019. , The public transport infrastructure in North America ... available in almost every corner of the region. The ... of public transport service providers are driving the North ...
(Date:7/12/2014)... 12, 2014 The report, "Phthalic Anhydride ... Market by Application & Geography – Trends & Forecast ... analysis and forecasting of market volume and value. The ... derivatives separately. The market of phthalic anhydride is projected ... to $8,415.89 million by 2018, with a CAGR of ...
(Date:7/12/2014)... Dallas, TX (PRWEB) July 12, 2014 ... training market research report, ‘cognitive assessment and ... able to monitor, assess, train, or enhance ... several uses such as in dementia screening, ... concussion management, classroom learning, self assessment, brain ...
Breaking Medicine News(10 mins):Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 3Health News:New Collection of Long Graduation Dresses Revealed by Fadhits.com 2Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 2Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 5
... prompt consumers, food industry to consider ... benefits of natural sea salt, ... a dinner plate - yet that,s exactly what millions,of Americans unwittingly ... table salt, says Mark Zoske, co-founder of SaltWorks, Inc.,( http://www.seasalt.com ), ...
... -- China,Shenghuo Pharmaceutical Holdings, Inc. (Amex: KUN ... in the research, development, manufacture,and marketing of pharmaceutical, ... of China ("PRC"), today announced it will,conduct a ... April 2, 2008, to,discuss the Company,s financial results ...
... ... Enroll in Wellness Programs and Believe, that Yoga, Tai Chi and Other ... ... grow in,popularity, employees overwhelmingly see value in these healthy activities,but don,t stay committed to ...
... - Reduce pollution, save money., CHICAGO, March 31 ... "green" record by launching an innovative Shared,Bike Program on ... The Museum is a trendsetter for employee bicycle ... showers and bike parking,including a large, secure, indoor bike-parking ...
... a leading provider of laser vision correction services ... 76th LasikPlus(R) vision,center in Woodbridge, New Jersey. This ... year, and the second vision center,located in Northern ... Paramus in April 2006., Similar to other ...
... Inc. (Nasdaq: STRM ) today announced the financial ... 31, 2008., Revenues in the fourth quarter of ... with $3.8 million in the fourth quarter of fiscal,year ... $781 thousand, a,153% increase, compared with an Operating Profit ...
Cached Medicine News:Health News:SaltWorks, Inc. Advises Table Salt Alternatives 2Health News:China Shenghuo Pharmaceutical Holdings, Inc. Schedules Conference Call to Discuss FY 2007 Results 2Health News:China Shenghuo Pharmaceutical Holdings, Inc. Schedules Conference Call to Discuss FY 2007 Results 3Health News:Guardian Survey: Despite Perceived Effectiveness, Most Employees Who Participate in Wellness Programs Do Not Stay Committed 2Health News:Guardian Survey: Despite Perceived Effectiveness, Most Employees Who Participate in Wellness Programs Do Not Stay Committed 3Health News:Guardian Survey: Despite Perceived Effectiveness, Most Employees Who Participate in Wellness Programs Do Not Stay Committed 4Health News:Field Museum Launches Shared Bike Program for Employees 2Health News:LCA-Vision Announces the Opening of its 76th LasikPlus(R) Vision Center in Woodbridge, New Jersey 2Health News:Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results 2Health News:Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results 3Health News:Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results 4Health News:Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results 5Health News:Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results 6Health News:Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results 7Health News:Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results 8Health News:Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results 9Health News:Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results 10Health News:Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results 11Health News:Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results 12Health News:Streamline Health Solutions, Inc. Reports Fourth Quarter and Fiscal Year 2007 Results 13
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Infusion Cannula, 6.0mm....
Subretinal Injection Cannula, Curved; 20g (0.90) x 1" (25mm); Tip Extension: 3mm, 32g (0.23); Angled at 35°....
Injection Cannula, Angled; 20g (0.90) x 1" (25mm); Tip Extension: 5mm, 30g (0.30); Angled at 45°, 2.5mm from Tip....
Medicine Products: